A study involving 203 gastric cancer patients revealed that total neoadjuvant therapy (TNT) resulted in a 5-year overall survival (OS) rate of 65.2% and a disease-specific survival (DSS) rate of 70.8%. Notably, patients achieving pathologic complete response (PCR) had significantly better outcomes, with 5-year OS at 89.1% and DSS at 96.9%. High rates of treatment completion (96.1%) and effective surgical approaches were observed, highlighting TNT’s potential in improving survival outcomes.
• Why it matters: Effective treatment options for gastric cancer are critically needed.
Journal Article by Song Y, Hirata Y (…) Badgwell BD et 7 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.